CSBio CSBio

X
[{"orgOrder":0,"company":"Green Cross Well-being","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GC Wellbeing Drug Material for Cancer Cachexia Shows Efficacy","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase II","country":"SOUTH KOREA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Green Cross Well-being"},{"orgOrder":0,"company":"LG Chem","sponsor":"Rhythm Pharmaceuticals","pharmaFlowCategory":"D","amount":"$305.0 million","upfrontCash":"$100.0 million","newsHeadline":"Rhythm Pharmaceuticals and LG Chem Life Sciences Enter Agreement for Rhythm to Acquire Global Rights to Oral MC4R Agonist LB54640","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase II","country":"SOUTH KOREA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","url1":"","url2":"","graph1":"Small molecule","graph2":"LG Chem"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            Under the agreement, Rhythm will acquire global rights for LB54640, an investigational oral small molecule MC4R agonist now in Phase 2 clinical trials for patients with acquired hypothalamic obesity and proopiomelanocortin, LEPR, or PCSK1 deficiency obesity.

            Lead Product(s): LB54640

            Therapeutic Area: Nutrition and Weight Loss Product Name: LB54640

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Rhythm Pharmaceuticals

            Deal Size: $305.0 million Upfront Cash: $100.0 million

            Deal Type: Licensing Agreement January 04, 2024

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The joint research team focused on analyzing the effects of GCWB204 on main biomarkers from animal samples that underwent muscle reduction upon the use of the chemotherapeutic drug 5-Fluorouracil.

            Lead Product(s): BST204

            Therapeutic Area: Nutrition and Weight Loss Product Name: GCWB204

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 25, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY